Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 8:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 99 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Cancer Thrombosis Clear all
Completed No phase listed Observational

Observational Studies in Cancer Associated Thrombosis for Rivaroxaban - United States Cohort

NCT04979780
View directory record Official record
Conditions
Treatment of Venous Thromboembolism in Cancer Patients, Prophylaxis of Recurrent Venous Thromboembolism in Cancer Patients
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Low molecular weight heparin (LMWH), Direct Oral Anticoagulants (DOAC)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
3,708 participants
Timeline
2021 – 2022
U.S. locations
1
States / cities
Multiple Locations, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Jul 23, 2026, 8:59 PM EDT
Completed Not applicable Interventional

EXercise Training for the Prevention of Cancer Thrombosis (EXPECT) Pilot Trial

NCT01853202
View directory record Official record
Conditions
Cancer Thrombosis
Interventions
Supervised aerobic exercise training
Behavioral
Lead sponsor
University of Vermont
Other
Eligibility
18 Years to 79 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Dec 3, 2014 · Synced Jul 23, 2026, 8:59 PM EDT
Terminated Phase 3 Interventional

A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE

NCT05171049
View directory record Official record
Conditions
Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolism
Interventions
Abelacimab, Apixaban
Biological · Drug
Lead sponsor
Anthos Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
23
States / cities
Aurora, Colorado • West Haven, Connecticut • Washington D.C., District of Columbia + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Jul 23, 2026, 8:59 PM EDT
Completed No phase listed Observational

Myeloproliferative Neoplasms (MPN) and COVID-19

NCT04385160
View directory record Official record
Conditions
Myeloproliferative Neoplasm, COVID
Interventions
Not listed
Lead sponsor
FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
Other
Eligibility
18 Years and older
Enrollment
552 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 14, 2025 · Synced Jul 23, 2026, 8:59 PM EDT
Recruiting Phase 2 Interventional

Neoadjuvant Lenvatinib and Pembrolizumab for IVC Tumor Thrombus

NCT05319015
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Neoadjuvant Lenvatinib, Neoadjuvant Pembrolizumab, Radical nephrectomy, IVC thrombectomy, retroperitoneal lymph node dissection, Adjuvant Pembrolizumab
Drug · Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced Jul 23, 2026, 8:59 PM EDT
Enrolling by invitation Not applicable Interventional

Implementing VTE Prevention in Ambulatory Cancer Care

NCT07292376
View directory record Official record
Conditions
Venous Thromboembolism, Neoplasms
Interventions
Clinical program
Other
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Jul 23, 2026, 8:59 PM EDT
Completed Phase 3 Interventional Results available

Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer

NCT03045406
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Apixaban, Dalteparin
Drug
Lead sponsor
Fadoi Foundation, Italy
Other
Eligibility
18 Years and older
Enrollment
1,170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
18
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Gainesville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2025 · Synced Jul 23, 2026, 8:59 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Neo-adjuvant SABR for IVC Tumor Thrombus in Newly Diagnosed RCC

NCT02473536
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Stereotactic ablative radiation therapy
Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Jul 23, 2026, 8:59 PM EDT
Completed Phase 1 Interventional

A Study of ALT-836 in Combination With Gemcitabine for Locally Advanced or Metastatic Solid Tumors

NCT01325558
View directory record Official record
Conditions
Locally Advanced Malignant Neoplasm, Malignant Solid Tumour
Interventions
ALT-836 in combination with gemcitabine
Biological
Lead sponsor
Altor BioScience
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
4
States / cities
Atlanta, Georgia • Iowa City, Iowa • Rochester, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Jul 23, 2026, 8:59 PM EDT
Completed Phase 2 Interventional Results available

Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer

NCT00381888
View directory record Official record
Conditions
Cervical Cancer, Endometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer, Sarcoma, Thromboembolism, Vaginal Cancer, Vulvar Cancer
Interventions
fondaparinux sodium
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
Minneapolis, Minnesota • Upland, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 27, 2017 · Synced Jul 23, 2026, 8:59 PM EDT
Active, not recruiting Not applicable Interventional

Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma

NCT02921022
View directory record Official record
Conditions
Pancreatic Cancer, Advanced Pancreatic Ductal Adenocarcinoma
Interventions
Gemcitabine, Nab-paclitaxel, PEGPH20
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
10
States / cities
Hartford, Connecticut • Miami, Florida • Basking Ridge, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Jul 23, 2026, 8:59 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Guilford Genomic Medicine Initiative (GGMI)

NCT01372553
View directory record Official record
Conditions
Breast Cancer, Ovarian Cancer, Colon Cancer, Thrombophilia
Interventions
Not listed
Lead sponsor
The Moses H. Cone Memorial Hospital
Other
Eligibility
18 Years and older
Enrollment
1,184 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Greensboro, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 15, 2014 · Synced Jul 23, 2026, 8:59 PM EDT
Not yet recruiting Phase 4 Interventional

Extended Prophylactic Anticoagulation Following Spinal Surgery for Metastatic Disease

NCT07713875
View directory record Official record
Conditions
Venous Thromboembolism (VTE), Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Spine Metastasis
Interventions
Apixaban
Drug
Lead sponsor
James Bayley
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Pittburgh, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Jul 23, 2026, 8:59 PM EDT
Completed No phase listed Observational

Epidemiology of Venous Thromboembolism

NCT00456196
View directory record Official record
Conditions
Venous Thromboembolism, Pulmonary Embolism, Cancer, Deep Vein Thrombosis, COPD
Interventions
Not listed
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
Not listed
Enrollment
5,451 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 12, 2009 · Synced Jul 23, 2026, 8:59 PM EDT
Completed No phase listed Observational

Rivaroxaban Utilization for Treatment and Prevention of Thromboembolism in Cancer Patients: Experience at a Comprehensive Cancer Center

NCT02502396
View directory record Official record
Conditions
Cancer, Deep-vein Thrombosis of the Lower and Upper Extremities, Pulmonary Embolism, Non-valvular Atrial Fibrillation
Interventions
Retrospective Chart Review
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 23, 2022 · Synced Jul 23, 2026, 8:59 PM EDT
Recruiting Phase 3 Interventional

DOAC - Dosing Options in AntiCoagulation Prophylaxis

NCT07005024
View directory record Official record
Conditions
Cancer, VTE (Venous Thromboembolism)
Interventions
Apixaban 2.5 mg twice daily, Apixaban 5 mg once daily, No anticoagulation
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
996 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Jul 23, 2026, 8:59 PM EDT
Recruiting Phase 3 Interventional

Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers

NCT07493304
View directory record Official record
Conditions
Venous Thromboembolism (VTE)
Interventions
REGN7508, Apixaban
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
2
States / cities
Hialeah, Florida • El Paso, Texas
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jul 23, 2026, 8:59 PM EDT
Completed No phase listed Observational

Safety and Feasibility of the Infinity Catheter for Radial Access

NCT04553549
View directory record Official record
Conditions
Brain Tumor, Stroke, Acute, Brain Aneurysm, Intracranial Arteriovenous Malformations, Carotid Stenosis, Cavernous Sinus Thrombosis
Interventions
Transradial approach
Device
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 10, 2023 · Synced Jul 23, 2026, 8:59 PM EDT
Completed Phase 2 Interventional

Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)

NCT01259817
View directory record Official record
Conditions
High Risk Polycythemia Vera, High Risk Essential Thrombocythemia
Interventions
PEGASYS, Aspirin
Drug
Lead sponsor
Ronald Hoffman
Other
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
16
States / cities
Scottsdale, Arizona • Palo Alto, California • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2017 · Synced Jul 23, 2026, 8:59 PM EDT
Completed Phase 4 Interventional Results available

Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma

NCT02958969
View directory record Official record
Conditions
Venous Thromboembolism, Multiple Myeloma
Interventions
Apixaban
Drug
Lead sponsor
Gregory Piazza
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Boston, Massachusetts • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Jul 23, 2026, 8:59 PM EDT
Terminated Phase 3 Interventional Results available

Anticoagulation and Inferior Vena Cava Filters in Cancer Patients With a Venous Thromboembolism

NCT00423683
View directory record Official record
Conditions
Cancer, Thromboembolism
Interventions
Arixtra alone, Arixtra + filter
Drug · Device
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Jun 7, 2016 · Synced Jul 23, 2026, 8:59 PM EDT
Completed No phase listed Observational

Heparin or Enoxaparin in Patients With Cancer

NCT00004875
View directory record Official record
Conditions
Lymphoma, Thromboembolism, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
enoxaparin, heparin
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 1999
U.S. locations
2
States / cities
Chicago, Illinois • Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 20, 2011 · Synced Jul 23, 2026, 8:59 PM EDT
Recruiting Phase 3 Interventional

The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer

NCT06861088
View directory record Official record
Conditions
Venous Thromboembolism, Metastatic Pancreatic Cancer, Locally Advanced Pancreatic Adenocarcinoma
Interventions
Kinisoquin™, Placebo
Drug
Lead sponsor
Quercis Pharma AG
Industry
Eligibility
18 Years and older
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
3
States / cities
Ventura, California • Miami Lakes, Florida • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 1, 2026 · Synced Jul 23, 2026, 8:59 PM EDT
Terminated Phase 2 Interventional

Tinzaparin for Primary Treatment and Extended Secondary Prophylaxis of Venous Thromboembolism in Patients With Cancer

NCT00981903
View directory record Official record
Conditions
Venous Thromboembolism, Cancer
Interventions
Tinzaparin sodium
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
2
States / cities
Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 5, 2017 · Synced Jul 23, 2026, 8:59 PM EDT